Safety study of ALXN2230 in healthy volunteers
This trial tests the safety and how the body handles a new drug called ALXN2230 in healthy people. It helps find the right dose and checks for side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are generally healthy, with no major medical conditions.
- Your IgG antibody levels are between 1000 and 1600 mg/dL.
- You have antibodies against tetanus (from vaccination or prior infection).
- You do not smoke and have not smoked for at least 1 year.
- Your body mass index (BMI) is between 18 and 32, and you weigh at least 50 kg (110 lbs).
- You have no history of serious infections, allergies to the drug ingredients, or recent blood loss or transfusions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new investigational drug called ADX-626 in healthy volunteers for the first time in humans. The goal is to see how the drug is processed by the body and whether it is safe, helping to decide if it can be studied in future patients.
This is an early-stage study testing a new investigational medicine called ALN-4915 in healthy volunteers. Researchers want to learn if it is safe and how the body processes it.
This study tests a new medicine called ALN-4285 in healthy adults to see how safe it is and how the body processes it. It may help find a new treatment for certain conditions.
This is an early-stage safety study testing a new experimental drug called REGN22044 in people with no serious health conditions. Researchers want to understand how safe the drug is, how well people tolerate it, and how the body processes it.
This trial tests the safety of a new drug called STLX-2012 in healthy people. It helps researchers understand how the drug works in the body before testing it in patients with a disease.
This study is an extension of a previous trial (study 301) for adults with a heart condition called transthyretin amyloid cardiomyopathy. It aims to evaluate the long-term safety and effectiveness of an investigational drug (ALXN2220). Participants who completed the earlier study without stopping the drug or withdrawing consent may be eligible to continue receiving the treatment.
Hear when a new Healthy Adult Participants trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.